Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has disclosed its employee stock ownership plan for 2026, aiming to raise a maximum of 33.608 million yuan, with participation from up to 145 individuals including directors, senior management, and key employees [1] - The employee stock ownership plan is closely tied to the company's performance over the next three years, with assessment indicators including both "operating revenue" and "assessed profit," targeting significant growth [1][2] - The plan outlines specific unlock periods and performance targets, with the first unlock period set for 2026, requiring operating revenue to reach 1 billion yuan and assessed profit to hit 270 million yuan [2] Group 2 - The company is expected to see significant revenue growth as several core products are set to be approved or submitted for approval, including a domestic first generic of lidocaine and prilocaine aerosol, which is anticipated to complete registration by 2026 [2][3] - Participants in the employee stock ownership plan are required to use their own funds for subscription, with shares sourced from the company's repurchased stock at a price of 16.93 yuan per share [3] - The company believes that this long-term mechanism of employee stock ownership will effectively motivate the core team's enthusiasm and creativity, promoting the research, market promotion, and sales of core products to ensure the achievement of high growth targets [3]

Core Viewpoint - The company, TianKang (301263.SZ), forecasts a significant decline in net profit for the fiscal year 2025, with expected figures between 25 million to 35 million yuan, representing a year-on-year decrease of 67.66% to 76.90% [1] Group 1: Financial Performance - The net profit attributable to shareholders is projected to be between 25 million to 35 million yuan, a decrease of 67.66% to 76.90% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 27 million to 37 million yuan, reflecting a year-on-year decline of 65.11% to 74.54% [1] Group 2: Business Segments - The company's core business in sexual health has experienced a decline in sales revenue due to increased competition and the number of competing products, although there are signs of a gradual market recovery [1] - The product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) has a strong brand moat, and the company plans to enhance brand promotion efforts to boost sales [1] - The launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1] Group 3: Product Challenges - The core product "He Wei Zheng Chang Wan" (Stomach and Intestine Regulating Pills) has seen a decline in sales due to production capacity issues at the Thai manufacturer and delays in imports [1] - The company is actively working on the registration and approval process for "He Wei Zheng Chang Wan" in China, aiming to resolve production capacity bottlenecks [1]

Core Viewpoint - The company Tainkang (301263) forecasts a significant decline in net profit for 2025, estimating a range of 25 million to 35 million yuan, representing a decrease of 67.66% to 76.9% compared to the previous year [2] Group 1: Business Performance - The core business segment of sexual health has experienced a decline in sales revenue due to increased competition and the number of competing products [2] - Despite the challenges, there is a noted trend of gradual market demand recovery [2] - The product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) has a strong brand moat, and the company plans to enhance brand promotion to boost sales [2] Group 2: Product Development and Challenges - The core product "He Wei Zheng Chang Wan" faced a decline in sales due to insufficient production capacity from the Thai manufacturer and delays in imports [2] - The company is actively working on the registration and approval process for "He Wei Zheng Chang Wan" in China to resolve production capacity bottlenecks [2] - The launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment [2] Group 3: Financial Outlook - The company plans to increase investment in research and development while also boosting brand promotion efforts, which will lead to higher sales expenses and compress profit margins [2]

每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王瀚黎） 每经AI快讯，泰恩康1月28日晚间发布公告称，公司第五届第十三次董事会会议于2026年1月28日以通 讯会议的方式召开。会议审议了《关于提请股东会授权董事会办理公司2026年员工持股计划有关事项的 议案》等文件。 ...

Core Viewpoint - The company expects a net profit of 25 million to 35 million yuan for the fiscal year 2025, representing a year-on-year decline of 67.66% to 76.90% due to increased competition and a decrease in sales revenue in its core sexual health business [1] Group 1: Financial Performance - The projected net profit for 2025 is between 25 million and 35 million yuan [1] - This represents a significant decline of 67.66% to 76.90% compared to the previous year [1] Group 2: Business Operations - The sexual health business has experienced a decline in sales revenue due to the increasing number of competitors and intense market competition [1] - However, there are signs of a gradual recovery in market demand [1] Group 3: Product Strategy - The company plans to strengthen brand promotion efforts for its product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) to boost sales [1] - The upcoming launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1]

Core Viewpoint - The company, 泰恩康, is forecasting a significant decline in net profit for 2025, with estimates ranging from 25 million to 35 million yuan, representing a year-on-year decrease of 67.66% to 76.90% [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 25 million and 35 million yuan, a decrease of 67.66% to 76.90% year-on-year [1] - The forecasted net profit excluding non-recurring gains and losses is estimated to be between 27 million and 37 million yuan, reflecting a year-on-year decline of 65.11% to 74.54% [1] Group 2: Business Segment Analysis - The company's core business in sexual health has experienced a decline in sales revenue due to increased competition and a growing number of competing products, although there are signs of a gradual market recovery [1] - The product "爱廷玖" (Dapoxetine Hydrochloride Tablets) has a strong brand presence, and the company plans to enhance brand promotion to boost sales [1] - The launch of the new product "爱廷列" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1] Group 3: Operational Challenges - The core product "和胃整肠丸" (Hewei Zhengchang Wan) has seen a decline in sales due to insufficient production capacity from Thai manufacturers and delays in imports [1] - The company is actively working on the registration and approval process for "和胃整肠丸" in China to address production capacity bottlenecks [1] Group 4: Investment and Expenses - In 2025, the company plans to increase investment in research and development while also intensifying brand promotion efforts, which will lead to higher sales expenses and compress profit margins [1]

广东泰恩康医药股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总 则 第一条 为进一步完善广东泰恩康医药股份有限公司（以下简称"公司"）董 事、高级管理人员的薪酬管理，建立科学有效的激励和约束机制，有效调动董事、 高级管理人员的积极性，确保公司发展战略目标的实现，根据《公司法》《上市 公司治理准则》《公司章程》等相关规定，在充分考虑公司实际情况和行业特点 的基础上，特制定本制度。 第二条 本制度适用的对象为公司董事以及《公司章程》规定的高级管理人 员。 第三条 为保障公司健康、持续、稳定发展，公司董事、高级管理人员的薪 酬制度遵循以下原则： （一）严格执行公司董事会及薪酬与考核委员会管理要求及规定； （二）体现收入水平符合公司规模与业绩的原则； （三）体现责权利对等的原则，薪酬与岗位价值高低、承担责任大小、个人 业绩相符； （四）体现公司长远利益的原则，与公司可持续发展的目标相符； 公司应当结合行业水平、发展策略、岗位价值等因素合理确定董事、高级管 理人员和普通职工的薪酬分配比例，推动薪酬分配向关键岗位、生产一线和紧缺 急需的高层次、高技能人才倾斜，促进提高普通职工薪酬水平。 （五）体现激励与约束并重、 ...

广东泰恩康医药股份有限公司 2026 年员工持股计划管理办法 二〇二六年一月 1 第一章 总则 第一条 为规范广东泰恩康医药股份有限公司（以下简称"泰恩康"或"公 司"）2026 年员工持股计划（以下简称"员工持股计划"、"本员工持股计划"） 的实施，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的 指导意见》（以下简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》（以下简称"《自律监管指引》"）等相关法 律、行政法规、规章、规范性文件和《公司章程》之规定，特制定本管理办法。 第二章 员工持股计划的制定 第二条 员工持股计划所遵循的基本原则 （一）依法合规原则 公司实施本员工持股计划，严格按照法律、行政法规的规定履行程序，真实、 准确、完整、及时地实施信息披露。任何人不得利用本员工持股计划进行内幕交 易、操纵证券市场等证券欺诈行为。 （二）自愿参与原则 公司实施本员工持股计划遵循公司自主决定，员工自愿参加的原则，公司不 以摊派、强行分配等方式强制员工参加本员工持股 ...

广东泰恩康医药股份有限公司 2026 年员工持股计划（草案） 证券简称：泰恩康 证券代码：301263 广东泰恩康医药股份有限公司 2026 年员工持股计划 （草案） $$\Xi{\cal O}\,\underline{{{\longrightarrow}}}\,\lambda\!\!\!\!/\,\pm\,\longrightarrow\,\mathbb{H}$$ 1 广东泰恩康医药股份有限公司 2026 年员工持股计划（草案） 声明 本公司及董事会全体成员保证本员工持股计划及其摘要内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 2 广东泰恩康医药股份有限公司 2026 年员工持股计划（草案） 风险提示 一、广东泰恩康医药股份有限公司（以下简称"泰恩康""公司"或"本公 司"）2026 年员工持股计划（草案）（以下简称"本员工持股计划草案"）须 经公司股东会批准后方可实施，本员工持股计划草案能否获得公司股东会批准， 存在不确定性。 二、有关公司 2026 年员工持股计划（以下简称"本员工持股计划"）的具 体的资金来源、出资金额、预计规模和具体实施方案等属初步结果，能否完成实 施，存在不确定性 ...

证券代码：301263 证券简称：泰恩康 公告编号：2026-006 广东泰恩康医药股份有限公司 关于公司 2026 年度董事、高级管理人员 薪酬及津贴方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2026 年 1 月 28 日召 开第五届董事会第十三次会议，审议了《关于公司 2026 年度董事、高级管理人 员薪酬及津贴方案的议案》，根据《广东泰恩康医药股份有限公司章程》《董事会 薪酬与考核委员会工作细则》等公司相关制度，经公司董事会薪酬与考核委员会 提议，结合公司经营规模等实际情况并参照行业薪酬水平，拟定 2026 年度公司 董事、高级管理人员薪酬和津贴方案如下： （二）竞争原则：薪酬水平需参照同行业及同地区上市公司标准，保持公司 薪酬的吸引力及在市场上的竞争力。 四、薪酬构成 公司董事和高级管理人员的薪酬由基本薪酬、绩效薪酬和中长期激励收入等 组成，基本薪酬结合行业薪酬水平、岗位职责和履职情况确定。绩效薪酬是与公 司年度目标绩效和个人绩效考核指标完成情况相挂钩，与公司可持续发展相协调。 绩效薪酬 ...